Clinical Trials
42 trialsEVAX
University Hospital, Bordeaux
SLM + Axitinib for Clear Cell RCC
University of Iowa
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Grupo Espanol de Tumores Neuroendocrinos
AXMUS-C
Imperial College London
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
M.D. Anderson Cancer Center
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
ALARICE
The University of Hong Kong
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Memorial Sloan Kettering Cancer Center
AXIPAN
Assistance Publique - Hôpitaux de Paris
NPC - AXEL Study : Axitinib-Avelumab
Chinese University of Hong Kong
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Lynkcell Europe
A-PREDICT
Institute of Cancer Research, United Kingdom
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
M.D. Anderson Cancer Center
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
City of Hope Medical Center
AXIPAP
Centre Leon Berard
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NAXIVA
Scottish Clinical Trials Research Unit
Expansion Trial for Axitinib In Head And Neck Cancer
University of Michigan Rogel Cancer Center
Axi-STS
Sheffield Teaching Hospitals NHS Foundation Trust
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
University of California, Irvine
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
Seoul National University Hospital
AXITINIB
University Health Network, Toronto
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
University of Wisconsin, Madison
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
University of Wisconsin, Madison
FavorAx
Kidney Cancer Research Bureau
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations, LLC
SGC-AX14
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
AxiGII
Universitair Ziekenhuis Brussel
GliAvAx
Universitair Ziekenhuis Brussel
A Study of Axitinib in Advanced Carcinoid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib
Chinese University of Hong Kong
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma
University of California, San Francisco
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
N08CPA
The Netherlands Cancer Institute
Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
National Taiwan University Hospital
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
University of Michigan Rogel Cancer Center
AXUS
Gustave Roussy, Cancer Campus, Grand Paris
Study of Axitinib and Temsirolimus in Solid Tumors
Emory University